SCHEMBL19769142

SCHEMBL19769142

NC(=O)c1cc2c(-c3ccccc3OC(F)(F)F)cncc2s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 9/20 0.61
GSK3A P49840 9/20 0.61
CDK5 Q00535 9/20 0.61
GSK3B P49841 8/20 0.61
CDK1 P06493 8/20 0.61
CDK2 P24941 8/20 0.61
DYRK1A Q13627 8/20 0.61
KDR P35968 8/20 0.61
PRKACA P17612 7/20 0.61
LIMK1 P53667 7/20 0.61
CSNK1D P48730 7/20 0.61
PRKCD Q05655 7/20 0.61
RPS6KA3 P51812 7/20 0.61
DAPK3 O43293 6/20 0.61
PLK1 P53350 6/20 0.61
PLK3 Q9H4B4 6/20 0.61
SGK2 Q9HBY8 6/20 0.61
CHEK2 O96017 6/20 0.61
FGFR3 P22607 6/20 0.61
MAPK9 P45984 6/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7056743 0.76 GSK3A (1.00) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL19769175 0.75 PIM1 (0.65) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL7053792 0.75 GSK3A (1.00) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL7050653 0.74 GSK3A (1.00) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL7057944 0.74 PIM1 (0.80) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL7056577 0.74 GSK3A (0.78) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL19780458 0.72 PIM1 (0.68) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL19769129 0.72 MAP3K8 (1.00) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL19769161 0.72 PIM1 (0.79) PIM1GSK3ACDK5GSK3BCDK1
SCHEMBL19780834 0.72 PIM1 (0.80) PIM1GSK3ACDK5GSK3BCDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10154992-B2 Compounds and methods for treating HIV infection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-12-18 US disclosed
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION NAKAMURA, ROBERT 2018-01-18 US disclosed
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION NAKAMURA, ROBERT 2018-01-18 US disclosed
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION NAKAMURA, ROBERT 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10154992-B2 Compounds and methods for treating HIV infection CD4, CCR5, MMP8 PIM1 1098/4885GSK3A 1892/4885CDK5 1897/4885
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION CD4, CCR5, MMP8 PIM1 1098/4885GSK3A 1892/4885CDK5 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.